Centre Asset Management LLC held its position in Stryker Corp. (NYSE:SYK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,370 shares of the medical technology company’s stock at the end of the second quarter. Stryker Corp. accounts for about 2.3% of Centre Asset Management LLC’s investment portfolio, making the stock its 13th largest position. Centre Asset Management LLC’s holdings in Stryker Corp. were worth $13,129,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Capital Research Global Investors raised its position in Stryker Corp. by 3.4% in the second quarter. Capital Research Global Investors now owns 32,980,782 shares of the medical technology company’s stock valued at $3,952,087,000 after buying an additional 1,095,549 shares during the period. Vanguard Group Inc. raised its position in Stryker Corp. by 1.9% in the second quarter. Vanguard Group Inc. now owns 21,428,963 shares of the medical technology company’s stock worth $2,567,833,000 after buying an additional 397,336 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Stryker Corp. by 2.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 11,990,001 shares of the medical technology company’s stock worth $1,436,761,000 after buying an additional 328,431 shares during the last quarter. BlackRock Fund Advisors raised its position in Stryker Corp. by 20.1% in the second quarter. BlackRock Fund Advisors now owns 6,280,516 shares of the medical technology company’s stock worth $752,594,000 after buying an additional 1,051,648 shares during the last quarter. Finally, FMR LLC raised its position in Stryker Corp. by 12.6% in the second quarter. FMR LLC now owns 4,156,578 shares of the medical technology company’s stock worth $498,082,000 after buying an additional 466,411 shares during the last quarter. 75.29% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Stryker Corp. (NYSE:SYK)

Stryker Corp. (NYSE:SYK) opened at 110.36 on Friday. Stryker Corp. has a one year low of $86.68 and a one year high of $123.55. The firm has a 50-day moving average price of $115.24 and a 200-day moving average price of $114.92. The firm has a market cap of $41.32 billion, a PE ratio of 25.12 and a beta of 0.86.

Stryker Corp. (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 27th. The medical technology company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The firm earned $2.83 billion during the quarter, compared to analyst estimates of $2.81 billion. During the same period last year, the company earned $1.25 earnings per share. The business’s revenue for the quarter was up 17.1% on a year-over-year basis. On average, equities analysts expect that Stryker Corp. will post $5.78 EPS for the current fiscal year.

SYK has been the topic of a number of recent analyst reports. Zacks Investment Research raised Stryker Corp. from a “sell” rating to a “hold” rating and set a $129.00 target price on the stock in a report on Monday, October 31st. Canaccord Genuity reissued a “buy” rating and set a $130.00 target price on shares of Stryker Corp. in a report on Sunday, July 24th. Credit Suisse Group AG reissued an “outperform” rating and set a $124.00 target price (up from $110.00) on shares of Stryker Corp. in a report on Tuesday, July 19th. BMO Capital Markets raised Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 target price on the stock in a report on Tuesday, November 1st. They noted that the move was a valuation call. Finally, SunTrust Banks Inc. initiated coverage on Stryker Corp. in a report on Thursday, October 13th. They set a “buy” rating and a $140.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $122.86.

In other news, Director Ronda E. Stryker sold 12,000 shares of the firm’s stock in a transaction on Monday, November 7th. The stock was sold at an average price of $118.22, for a total value of $1,418,640.00. Following the completion of the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at $22,833,247.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 18,000 shares of the firm’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $116.13, for a total value of $2,090,340.00. Following the completion of the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at $22,429,580.46. The disclosure for this sale can be found here. 7.80% of the stock is owned by insiders.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.